A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Clinical trial NCT06892522 · RECRUITING

Trial details

NCT number: NCT06892522
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2025-06-30
Primary completion: 2035-12-01
Enrollment: 602

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.